Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis DiagnosisRecruiting
NCT06978660N/AUpdated Jul 20, 2026
Sponsor: Idoven 1903 S.L.
Transthyretin Cardiac Amyloidosis
United States, France, Germany, Spain, United Kingdom
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Active Not Recruiting
NCT07128615Phase 1, Phase 2Updated Jul 20, 2026
Sponsor: AstraZeneca
Influenza A
United States
ALICIA (Acalabrutinib in CLL Therapy)Completed
NCT04746950N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Russia
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological MalignanciesActive Not Recruiting
NCT04395079Phase 2Updated Jul 17, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Metastatic Malignant Female Reproductive System Neoplasm · Platinum-Resistant Malignant Female Reproductive System Neoplasm · Recurrent Malignant Female Reproductive System Neoplasm · Refractory Malignant Female Reproductive System Neoplasm
United States
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Recruiting
NCT06380738N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
Germany
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive Not Recruiting
NCT03732677Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Muscle Invasive Bladder Cancer
United States, Australia, Belgium, Brazil, Canada +17 more
A Phase 2 Study of ABSK043 Combined With OsimertinibNot Yet Recruiting
NCT07710612Phase 2Updated Jul 17, 2026
Sponsor: Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
China
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseRecruiting
NCT06314282N/AUpdated Jul 17, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus (SLE)
Argentina, China, Costa Rica, Egypt, Guatemala +7 more
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain CancerActive Not Recruiting
NCT03423628Phase 1Updated Jul 17, 2026
Sponsor: AstraZeneca
Recurrent Glioblastoma Multiforme · Primary Glioblastoma Multiforme · Brain Neoplasms, Malignant · Leptomeningeal Disease (LMD)
United States, Japan, United Kingdom
Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)Recruiting
NCT06705764Phase 4Updated Jul 17, 2026
Sponsor: University of Alberta
Severe Asthma
Canada
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaActive Not Recruiting
NCT05692180Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, France, Italy, Poland +4 more
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in SpainActive Not Recruiting
NCT06746116Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Advanced or Recurrent Endometrial Cancer
Spain
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Not Yet Recruiting
NCT07711002Phase 3Updated Jul 17, 2026
Sponsor: AstraZeneca
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Canada
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body RadiotherapyTerminated
NCT03148327Phase 1, Phase 2Updated Jul 16, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
United States, Australia
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminated
NCT03075527Phase 2Updated Jul 16, 2026
Sponsor: Dana-Farber Cancer Institute
Mesothelioma
United States
A Study of AZD4063 in PLN R14del Dilated CardiomyopathyRecruiting
NCT07241104Phase 1Updated Jul 16, 2026
Sponsor: AstraZeneca
Dilated Cardiomyopathy
Netherlands
Selumetinib for NF2-Related SchwannomatosisNot Yet Recruiting
NCT07707947Phase 2Updated Jul 16, 2026
Sponsor: Beijing Tiantan Hospital
Neurofibromatosis Type 2 · NF2 · NF2-related Schwannomatosis · Meningioma
China
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Recruiting
NCT07005128Phase 3Updated Jul 16, 2026
Sponsor: Amgen
Small-cell Lung Cancer · Extensive Stage Small-cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active Not Recruiting
NCT03043872Phase 3Updated Jul 16, 2026
Sponsor: AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
United States, Argentina, Austria, Brazil, Bulgaria +18 more
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHActive Not Recruiting
NCT07000136Phase 3Updated Jul 16, 2026
Sponsor: AstraZeneca
Heterozygous Familial Hypercholesterolaemia
United States, Argentina, Australia, Brazil, Bulgaria +19 more
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United StatesCompleted
NCT05329194Phase 4Updated Jul 16, 2026
Sponsor: AstraZeneca
Asthma
United States
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruiting
NCT04169737Phase 2Updated Jul 16, 2026
Sponsor: M.D. Anderson Cancer Center
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Small Lymphocytic Lymphoma
United States
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine CareActive Not Recruiting
NCT06422689Phase 4Updated Jul 16, 2026
Sponsor: AstraZeneca
Asthma
United States
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusRecruiting
NCT07288515N/AUpdated Jul 16, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Belarus
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerRecruiting
NCT07181161Phase 1, Phase 2Updated Jul 15, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Brazil, China, France, Italy +5 more

Previous page Next page